CI

At a glance

ClinicalIndex Comparison Record
Phase 2Recruiting· 124 target
Drug / intervention
chemotherapy +1 moredrug
Likely dose
Not stated in record
Key inclusion· 7
  • ✓First recurrence of platinum-sensitive invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer
  • ✓Progression-free interval of at least 6 months after platinum-containing therapy
  • ✓Progressed during PARP inhibitor maintenance
  • ✓Age 18 years or older
Key exclusion· 11
  • ✕Non-epithelial tumors or borderline tumors
  • ✕No recurrence scheduled for diagnostic/second-look or debulking surgery
  • ✕More than one prior chemotherapy line
  • ✕Second, third, or later recurrence

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

In the news

1 article

Matched to this trial by ClinicalIndexfrom reputable biotech & medical press.

Search/NCT05704621
NCT05704621Phase 2RecruitingOn TrackUpdated 15mo ago
CompareCT.gov

A Randomized Phase II Study of Secondary Cytoreductive Surgery (CRS) in Patients With Relapsed Ovarian Cancer Who Have Progressed on PARP Inhibitor Maintenance

Korea University Guro Hospital·interventional·Posted Jan 30, 2023·Updated Mar 6, 2025

In Brief

A Phase 2 clinical trial evaluating secondary cytoreductive surgery and chemotherapy for Ovarian Cancer and Drug Related Neoplasm/Cancer. Currently recruiting, targeting 124 participants across 1 site.

Detailed Summary

This is a randomized phase II study of secondary cytoreductive surgery (CRS) in patients with relapsed ovarian cancer who have progressed on PARP inhibitor maintenance.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer, Drug Related Neoplasm/Cancer
CountriesSouth Korea
CollaboratorsBoryung Pharmaceutical Co., Ltd, Chong Kun Dang Pharmaceutical Corp., Yonsei University, KGOG: Korean Gynaelogical Onology Group, Korea, Japanese Gynecologic Oncology Group, Asia-Pacific Gynecologic Oncology Trials Group

Timeline

Phase 2Recruiting
2023202420252026202720282029
First PostedJan 30, 2023
Enrollment StartDec 1, 2023
Primary CompletionDec 28, 2026
Study CompletionDec 28, 2028
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 3.4 years agoPrimary completion in 6 months

Interventions

secondary cytoreductive surgeryprocedure

Maximum effort cytoreductive surgery

chemotherapydrug

six cycles of platinum-based chemotherapy +/- bevacizumab